Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function.

Spruss A, Kanuri G, Stahl C, Bischoff SC, Bergheim I.

Lab Invest. 2012 Jul;92(7):1020-32. doi: 10.1038/labinvest.2012.75. Epub 2012 Apr 23.

2.

Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice.

Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I.

Hepatology. 2009 Oct;50(4):1094-104. doi: 10.1002/hep.23122.

PMID:
19637282
3.

Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model.

Wagnerberger S, Spruss A, Kanuri G, Stahl C, Schröder M, Vetter W, Bischoff SC, Bergheim I.

J Nutr Biochem. 2013 Mar;24(3):531-8. doi: 10.1016/j.jnutbio.2012.01.014. Epub 2012 Jun 27.

PMID:
22749137
4.

Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice.

Haub S, Kanuri G, Volynets V, Brune T, Bischoff SC, Bergheim I.

Am J Physiol Gastrointest Liver Physiol. 2010 Mar;298(3):G335-44. doi: 10.1152/ajpgi.00088.2009. Epub 2009 Aug 27.

5.

Fructose-induced steatosis in mice: role of plasminogen activator inhibitor-1, microsomal triglyceride transfer protein and NKT cells.

Kanuri G, Spruss A, Wagnerberger S, Bischoff SC, Bergheim I.

Lab Invest. 2011 Jun;91(6):885-95. doi: 10.1038/labinvest.2011.44. Epub 2011 Mar 21.

6.

Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis.

Wagnerberger S, Spruss A, Kanuri G, Volynets V, Stahl C, Bischoff SC, Bergheim I.

Br J Nutr. 2012 Jun;107(12):1727-38. doi: 10.1017/S0007114511004983. Epub 2011 Oct 10.

PMID:
22018861
7.

Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice.

Kanuri G, Spruss A, Wagnerberger S, Bischoff SC, Bergheim I.

J Nutr Biochem. 2011 Jun;22(6):527-34. doi: 10.1016/j.jnutbio.2010.04.007. Epub 2010 Aug 30.

PMID:
20801629
8.
9.

Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice.

Spruss A, Kanuri G, Uebel K, Bischoff SC, Bergheim I.

Antioxid Redox Signal. 2011 Jun;14(11):2121-35. doi: 10.1089/ars.2010.3263. Epub 2011 Mar 16.

PMID:
21083420
10.

Protective effect of bile acids on the onset of fructose-induced hepatic steatosis in mice.

Volynets V, Spruss A, Kanuri G, Wagnerberger S, Bischoff SC, Bergheim I.

J Lipid Res. 2010 Dec;51(12):3414-24. doi: 10.1194/jlr.M007179. Epub 2010 Sep 16.

11.

Cinnamon extract protects against acute alcohol-induced liver steatosis in mice.

Kanuri G, Weber S, Volynets V, Spruss A, Bischoff SC, Bergheim I.

J Nutr. 2009 Mar;139(3):482-7. doi: 10.3945/jn.108.100495. Epub 2009 Jan 6.

12.

Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake.

Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Königsrainer A, Maier KP, Bischoff SC, Bergheim I.

J Nutr. 2008 Aug;138(8):1452-5.

13.

Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.

Liu LF, Purushotham A, Wendel AA, Belury MA.

Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1671-82. Epub 2007 Feb 22.

14.

Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin.

Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, McClain CJ, Bischoff SC.

J Hepatol. 2008 Jun;48(6):983-92. doi: 10.1016/j.jhep.2008.01.035. Epub 2008 Mar 14.

PMID:
18395289
15.

[Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].

Zhang DM, Zhang GY, Wang T, Zhong HJ, Chen WK.

Zhonghua Yi Xue Za Zhi. 2006 May 16;86(18):1279-83. Chinese.

PMID:
16796890
16.

Puerarin ameliorates experimental alcoholic liver injury by inhibition of endotoxin gut leakage, Kupffer cell activation, and endotoxin receptors expression.

Peng JH, Cui T, Huang F, Chen L, Zhao Y, Xu L, Xu LL, Feng Q, Hu YY.

J Pharmacol Exp Ther. 2013 Mar;344(3):646-54. doi: 10.1124/jpet.112.201137. Epub 2012 Dec 31.

17.

Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis.

Sugino H, Kumagai N, Watanabe S, Toda K, Takeuchi O, Tsunematsu S, Morinaga S, Tsuchimoto K.

J Gastroenterol Hepatol. 2008 Dec;23(12):1909-16. doi: 10.1111/j.1440-1746.2008.05393.x. Epub 2008 Apr 19.

PMID:
18422963
18.

Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment.

Vilà L, Rebollo A, Ađalsteisson GS, Alegret M, Merlos M, Roglans N, Laguna JC.

Toxicol Appl Pharmacol. 2011 Feb 15;251(1):32-40. doi: 10.1016/j.taap.2010.11.011. Epub 2010 Nov 29.

PMID:
21122807
19.

Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity.

Woo SL, Xu H, Li H, Zhao Y, Hu X, Zhao J, Guo X, Guo T, Botchlett R, Qi T, Pei Y, Zheng J, Xu Y, An X, Chen L, Chen L, Li Q, Xiao X, Huo Y, Wu C.

PLoS One. 2014 Mar 17;9(3):e91111. doi: 10.1371/journal.pone.0091111. eCollection 2014.

20.

High-fat, high-fructose diet induces hepatic iron overload via a hepcidin-independent mechanism prior to the onset of liver steatosis and insulin resistance in mice.

Tsuchiya H, Ebata Y, Sakabe T, Hama S, Kogure K, Shiota G.

Metabolism. 2013 Jan;62(1):62-9. doi: 10.1016/j.metabol.2012.06.008. Epub 2012 Jul 30.

PMID:
22854109
Items per page

Supplemental Content

Write to the Help Desk